MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q2
hinzugefügt 03.08.2023
Axcella Health Operativer Cashflow 2011-2026 | AXLA
Operativer Cashflow Jährlich Axcella Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -69.6 M | -54.2 M | -49.8 M | -51 M | -30.7 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -30.7 M | -69.6 M | -51.1 M |
Operativer Cashflow Vierteljährlich Axcella Health
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.8 M | -5.1 M | - | -54 M | -35.5 M | -16.9 M | - | -40.6 M | -28.4 M | -14.1 M | - | -39.7 M | -29 M | -16.5 M | - | -37.6 M | -25.4 M | -12.2 M | - | -23.1 M | -15.7 M | -8.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -5.1 M | -54 M | -24.2 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
-82.5 M | $ 8.74 | 0.23 % | $ 86.4 M |  USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.62 | -1.09 % | $ 8.71 B |  Australia |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 98.41 | 1.77 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
181 M | $ 4.71 | 4.9 % | $ 760 M |  Britain |
 |
Cabaletta Bio
CABA
|
-131 M | $ 3.26 | 1.87 % | $ 328 M | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Brainstorm Cell Therapeutics
BCLI
|
-6.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-235 M | - | - | $ 546 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
156 M | $ 21.38 | 0.09 % | $ 999 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-31.1 M | - | - | $ 169 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
-18.1 M | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
68 M | $ 1.56 | 6.12 % | $ 401 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.05 | 4.45 % | $ 5.02 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
-52.4 M | $ 4.15 | -0.95 % | $ 444 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 25.09 | 4.02 % | $ 3.19 B | USA |
 |
Chimerix
CMRX
|
-69.1 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-55.2 M | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
-211 M | $ 33.33 | 2.27 % | $ 2.21 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.48 | 0.68 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
-177 M | - | - | $ 1.41 B | USA |
 |
Evogene Ltd.
EVGN
|
-24.7 M | $ 0.82 | 0.02 % | $ 27.9 M | Israel |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
|
Forte Biosciences
FBRX
|
-50.9 M | $ 32.42 | 5.95 % | $ 420 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-13.8 M | $ 2.64 | 8.42 % | $ 1.17 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
5.96 B | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
CTI BioPharma Corp.
CTIC
|
-81.2 M | - | - | $ 1.2 B | USA |